


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this document, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this document.*



**CK Life Sciences Int'l. (Holdings) Inc.**

長江生命科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0775)

## **NOTICE OF EXTRAORDINARY GENERAL MEETING**

**NOTICE IS HEREBY GIVEN** that an Extraordinary General Meeting of the shareholders of CK Life Sciences Int'l. (Holdings) Inc. (the “Company”) will be held at the Grand Ballroom, 1st Floor, Harbour Grand Hong Kong, 23 Oil Street, North Point, Hong Kong on Wednesday, 29th August, 2012 at 11:30 a.m. for the purposes of considering and, if thought fit, passing the following resolutions as ordinary resolutions:

### **ORDINARY RESOLUTIONS**

1. (1) **“THAT** subject to and conditional upon the approval of the shareholders of Polynoma, Inc. (“Polynoma”) for the adoption of the Polynoma’s 2012 Equity Incentive Plan (“Polynoma Equity Incentive Plan”) (the terms of which are set out in the document marked “A” tabled at the Extraordinary General Meeting and a summary of which is set out in Appendix I to the circular (“Circular”) of the Company dated 13th August, 2012 to which this notice forms part) (“Condition”), the Polynoma Equity Incentive Plan be and is hereby approved, adopted and implemented with effect from the date of the Extraordinary General Meeting or the date on which the Condition set out in this resolution having been fulfilled, whichever is the later and shall become effective on the date immediately preceding the date that the United States Securities and Exchange Commission declares Polynoma’s Registration Statement on Form S-1 in connection with the Proposed IPO (as defined below) to be effective (“Effective Date”) and **THAT** the director(s) of Polynoma be and are hereby authorised to grant options and to allot, issue and deal with the shares of the common stock of Polynoma (“Common Stock”) fall to be issued pursuant to the exercise of any option granted thereunder and to do all such acts and to enter into all such transactions, arrangements and agreements as may be necessary or expedient to implement and administer the Polynoma Equity Incentive Plan.”
- (2) **“THAT** subject to resolution 1(1) above being approved, the proposed grant of the options under the Polynoma Equity Incentive Plan to the grantees (“Grantees”) in the manner as set out in Appendix II to the Circular (“Proposed Grant”) be and is hereby approved with effect from the date (“Listing Date”) on which the Common Stock is listed on NASDAQ Stock Market (“Proposed IPO”), and in connection with the Proposed Grant:

- (i) the 10% limit (“Mandate Limit”) on the total number of shares of the Common Stock which may be issued upon the exercise of all options granted under the Polynoma Equity Incentive Plan be “refreshed” with effect from the Listing Date such that the Mandate Limit (excluding all options granted under the Proposed Grant) as “refreshed” will be 10% of the shares of Common Stock in issue as of the Listing Date (as enlarged after giving effect to the Proposed IPO and calculated on a fully diluted basis), be and is hereby approved with effect from the Listing Date;
  - (ii) the grant of options to certain Grantees to allow each Grantee to subscribe for more than 1% of the shares of Common Stock in issue as of the Listing Date (as enlarged after giving effect to the Proposed IPO and calculated on a fully diluted basis) under the Proposed Grant be and are hereby approved with effect from the Listing Date; and
  - (iii) the director(s) of Polynoma be and are hereby authorised to grant options and to allot, issue and deal with the shares of the Common Stock fall to be issued pursuant to the exercise of any option granted under the Proposed Grant and to do all such acts and to enter into all such transactions, arrangements and agreements as may be necessary or expedient to implement and give effect to the Proposed Grant.
2. “**THAT** where the Company’s board of directors declares, in accordance with the Company’s articles of association and the Companies Law of Cayman Islands, a special dividend on the shares of the Company in relation to the proposed spin-off of Polynoma for a separate listing on NASDAQ Stock Exchange, the satisfaction of such dividend wholly or in part by way of distribution of such amount of the Company’s interest in Polynoma as the directors of the Company (“Directors”) may determine (“Distribution in specie”) be and is hereby approved and **THAT** the Directors be and are hereby authorised to do all such acts and to enter into all such transactions, arrangements and agreements as may be necessary or expedient to implement and administer the Distribution in specie.”

By Order of the Board  
**Eirene Yeung**  
*Company Secretary*

Hong Kong, 13th August, 2012

*Notes:*

- (a) At the Extraordinary General Meeting, the Chairman of the Meeting will put each of the above resolutions to be voted by way of a poll under Article 80 of the Company’s Articles of Association.
- (b) Any member entitled to attend and vote at the Extraordinary General Meeting is entitled to appoint more than one proxy to attend and on a poll, vote in his stead. A proxy need not be a member of the Company.
- (c) To be valid, the proxy form together with any power of attorney or other authority (if any) under which it is signed or a notarially certified copy of such power or authority must be deposited at the Company’s principal place of business at 7th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong not later than 48 hours before the time appointed for holding the Extraordinary General Meeting or any adjournment thereof (as the case may be).

- (d) Completion and return of the proxy form will not preclude a member from attending and voting at the Extraordinary General Meeting or any adjournment thereof (as the case may be) should the member so desire.
- (e) The Register of Members of the Company will be closed from Friday, 24th August, 2012 to Wednesday, 29th August, 2012, both days inclusive, during which period no transfer of shares will be effected. In order to determine the entitlement to attend and vote at the Extraordinary General Meeting, all share certificates with completed transfer forms, either overleaf or separately, must be lodged with the Company's Branch Share Registrar, Computershare Hong Kong Investor Services Limited at Rooms 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Hong Kong, not later than 4:30 p.m. on Thursday, 23rd August, 2012.
- (f) In relation to Ordinary Resolutions Nos. 1(1) and 1(2) above, a summary containing the information necessary to enable the shareholders of the Company to make an informed decision on whether to vote for or against the resolutions, as required by the Rules Governing the Listing of Securities on The Hong Kong Stock Exchange of Hong Kong Limited, is set out in Appendix I and Appendix II to the Company's circular dated 13th August, 2012.
- (g) If typhoon signal no. 8 or above remains hoisted or a black rainstorm warning signal is in force at 9:30 a.m. at the date of the Extraordinary General Meeting, the Extraordinary General Meeting will be postponed. Members are requested to visit the website of the Company at [www.ck-lifesciences.com](http://www.ck-lifesciences.com) for details of alternative meeting arrangements.

The Extraordinary General Meeting will be held as scheduled when an amber or red rainstorm warning signal is in force.

Members who have any queries concerning the alternative meeting arrangements, please call the Company at (852) 2128 8888 during business hours from 9:00 a.m. to 5:00 p.m. on Mondays to Fridays, excluding public holidays.

Members should make their own decision as to whether they would attend the Extraordinary General Meeting under bad weather conditions bearing in mind their own situation and if they should choose to do so, they are advised to exercise care and caution.

- (h) The translation into Chinese language of this notice is for reference only. In case of any inconsistency, the English version shall prevail.

*As at the date of this document, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel and Dr. Chu Kee Hung; and the Non-executive Directors are Mr. Peter Peace Tulloch, Professor Wong Yue-chim, Richard (Independent Non-executive Director), Mrs. Kwok Eva Lee (Independent Non-executive Director) and Mr. Colin Stevens Russel (Independent Non-executive Director).*